Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06111430
Other study ID # 202200464B0
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 11, 2022
Est. completion date April 10, 2026

Study information

Verified date April 2023
Source Chang Gung Memorial Hospital
Contact Chi-Hung Liu
Phone (03)3281200
Email ivanliu001@cgmh.org.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Head and neck cancer is a group of cancers develop from the soft tissues, salivary gland, mucosa of the upper respiratory or digestive system covering the oral and nasal cavity. Radiotherapy is usually the standard treatment of Head and neck cancers. In the present study, investigators aim to study the prevalence of cervical-cranial vascular complications during the early stages in these Head and neck cancer patients receiving Radiotherapy. Investigators will also compare the results between Nasopharyngeal cancer and other Head and neck cancerpatients receiving Radiotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 800
Est. completion date April 10, 2026
Est. primary completion date April 10, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 100 Years
Eligibility Population: Prospective cohort Inclusion Criteria: 1. Age =20 years. 2. Head and neck cancer patient . 3. Had ever received radiation therapy (RT) ? 72 months before inclusion in the registry. 4. Had = 1 brain images and cervical-cranial vascular studies between the end of RT and d date of enrolment. Exclusion Criteria: 1. Age <20 years. 2. Patients not willing to sign the informed consent. Population: Retrospective validation cohort Inclusion Criteria: 1. Age =20 years. 2. Head and neck cancer patient. 3. Had ever received radiation therapy (RT) > 120 months before the adoption date of IRB at the participant site. 4. Had = 2 brain images and cervical-cranial vascular studies between the end of RT and 6~10 years after RT, one within 5 years after RT, the other after 5 years after RT. Exclusion Criteria: 1.Age <20 years.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Taiwan Chang Gung Memorial Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Significant CAS at internal carotid artery or common carotid artery We define significant CAS as (a) >50% stenosis on the B-mode with peak systolic velocities =120 cm/s based on the hemodynamic criteria at any internal carotid artery or common carotid artery in the CDU study according to the standard ultrasound criteria35; or (b) > 50% diameter stenosis on the follow up CT or MR images. 1 year
Primary Cerebral infarctions (CI) The CI is defined whenever there were symptomatic IS occurrence of presence of asymptomatic IS on the reviewed brain MRIs. 1 year
Primary Significant extracranial vertebral artery stenosis (VAS) > 50% diameter stenosis on the follow up CT or MR images. 1 year
Primary Significant intracranial artery stenosis Presence of > 50% stenosis at intracranial ICA/VA, basilar artery, middle cerebral artery, anterior cerebral artery, or anterior cerebral artery. 1 year
Primary Presence of carotid blow-out syndrome Carotid blow out syndrome was categorized as type 1 (threaten type), type 2 (impending blowouts), and type 3 (acute CBS hemorrhage). 1 year
Primary Presence of TLN We will identify white matter lesions, contrast-enhanced lesions, Cysts, and local mass effect. The white matter lesions in the temporal lobe will be divided into three groups: mild (small focal areas), moderate (larger confluent areas) and severe (large confluent areas extending outside the radiation field with or without local mass effect). The cysts will be evaluated for size and number. The local mass effect will be classified as mild (affecting only the temporal lobe sulci), moderate (affecting the sulci and ventricles) and severe (affecting the midline of the brain). 1 year
Primary Presence of hypothyroidism Clinical hypothyroidism was diagnosed when a patient had free T4 = 0.80 ng/dL with elevated TSH (>5.0 mU/L). 1 year
Primary Tumor recurrence Relapse 1 year
Primary Mortality Death 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04486573 - Cardiac Effects From Radiation Therapy by MRI N/A